PL1901783T3 - Kwas gentyzynowy do stabilizowania środków radiofarmaceutycznych 123-i - Google Patents

Kwas gentyzynowy do stabilizowania środków radiofarmaceutycznych 123-i

Info

Publication number
PL1901783T3
PL1901783T3 PL06726619T PL06726619T PL1901783T3 PL 1901783 T3 PL1901783 T3 PL 1901783T3 PL 06726619 T PL06726619 T PL 06726619T PL 06726619 T PL06726619 T PL 06726619T PL 1901783 T3 PL1901783 T3 PL 1901783T3
Authority
PL
Poland
Prior art keywords
radiopharmaceutical agents
stabilizing
gentic acid
gentic
acid
Prior art date
Application number
PL06726619T
Other languages
English (en)
Inventor
Ton Janssen
Den Bos Jan Van
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of PL1901783T3 publication Critical patent/PL1901783T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL06726619T 2005-07-11 2006-03-31 Kwas gentyzynowy do stabilizowania środków radiofarmaceutycznych 123-i PL1901783T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0514087.6A GB0514087D0 (en) 2005-07-11 2005-07-11 Stabilised radiopharmaceutical compositions
EP06726619.7A EP1901783B1 (en) 2005-07-11 2006-03-31 Gentisic acid for stabilising 123-i radiopharmaceuticals
PCT/GB2006/001215 WO2007007021A1 (en) 2005-07-11 2006-03-31 Gentisic acid for stabilisig 123-i radiopharmaceuticals

Publications (1)

Publication Number Publication Date
PL1901783T3 true PL1901783T3 (pl) 2015-03-31

Family

ID=34896966

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06726619T PL1901783T3 (pl) 2005-07-11 2006-03-31 Kwas gentyzynowy do stabilizowania środków radiofarmaceutycznych 123-i

Country Status (10)

Country Link
US (1) US8188296B2 (pl)
EP (1) EP1901783B1 (pl)
JP (1) JP5341512B2 (pl)
CN (1) CN101257929B (pl)
DK (1) DK1901783T3 (pl)
ES (1) ES2527531T3 (pl)
GB (1) GB0514087D0 (pl)
PL (1) PL1901783T3 (pl)
PT (1) PT1901783E (pl)
WO (1) WO2007007021A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
EP2214722A1 (en) * 2007-11-07 2010-08-11 GE Healthcare BV Stabilization of radiopharmaceuticals
CN102458396B (zh) 2009-04-15 2017-05-10 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
AU2011231721B2 (en) 2010-03-23 2014-08-14 Ge Healthcare As Preparation of stabilised X-ray diagnostic composition
WO2011147762A2 (en) 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
US20120264949A1 (en) * 2011-04-13 2012-10-18 Atomic Energy Council-Institute Of Nuclear Energy Research Method of Labeling Dopamine D2 Receptor Using Radiosynthesized Ligand of Iodine-123-Epidepride
US10048254B2 (en) * 2013-06-04 2018-08-14 Albany Medical College Cyclic-di-AMP specific detection
EP3888694A1 (en) 2014-10-24 2021-10-06 Molecular Insight Pharmaceuticals, Inc. Preparations of meta-iodobenzylguanidine and precursors thereof
CA3016901C (en) 2016-03-07 2023-06-13 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
JP6837895B2 (ja) * 2017-04-04 2021-03-03 日本化薬株式会社 医薬品溶液製剤の製造方法
US11351276B2 (en) * 2018-06-22 2022-06-07 Jubilant Draximage Inc. Radiopharmaceutical compositions of radioactive halogenated benzylguanidine
EP3976025A4 (en) * 2019-05-24 2023-05-17 Clarity Pharmaceuticals Limited PSMA IMAGING AGENT FORMULATIONS
US20230390426A1 (en) * 2020-10-22 2023-12-07 Nihon Medi-Physics Co., Ltd. Method for producing radioactive zirconium complex

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497744A (en) * 1978-03-31 1985-02-05 Mallinckrodt, Inc. Gentisic acid salts as radiographic scanning agent stabilizers
US4233284A (en) * 1978-03-31 1980-11-11 The Procter & Gamble Company Stabilized radiographic scanning agents
US4942231A (en) 1984-05-24 1990-07-17 Mallinckrodt, Inc. Method of preparing a chlorinated, brominated, radio-brominated, iodinated and/or radioiodinated aromatic or heteroaromatic compound
BE899739A (nl) * 1984-05-24 1984-11-26 Univ Bruxelles Werkwijze voor het controleren van de substitutie op aromatische kern,en, werkwijze en apparatuur ter bereiding van samenstelling voor scintigrafisch onderzoek.
US5306482A (en) 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
DE69231469T2 (de) * 1991-08-29 2001-01-25 Mallinckrodt Medical, Inc. Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
US5314678A (en) * 1992-01-28 1994-05-24 Mallinckrodt Medical, Inc. Sodium iodide 131 I capsules
CA2334146C (en) * 1998-06-02 2008-11-18 The Dow Chemical Company Radioiodinated phenols for brachytherapy
WO2002004030A2 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法

Also Published As

Publication number Publication date
US8188296B2 (en) 2012-05-29
DK1901783T3 (en) 2015-01-19
CN101257929A (zh) 2008-09-03
CN101257929B (zh) 2012-05-23
JP2009500441A (ja) 2009-01-08
JP5341512B2 (ja) 2013-11-13
WO2007007021A1 (en) 2007-01-18
PT1901783E (pt) 2015-02-05
GB0514087D0 (en) 2005-08-17
US20090005595A1 (en) 2009-01-01
ES2527531T3 (es) 2015-01-26
EP1901783A1 (en) 2008-03-26
EP1901783B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
LTC1912503I2 (lt) Fungicidiniai mišiniai, turintys 1-metilpirazol-4-ilo karboksirūgšties anilidus
DK3385253T3 (da) Kontrastmidler til myocardial perfusionsbilleddannelse
ATE431152T1 (de) Verbesserte ophthamologische bimatoprost-lösung
HUS1400051I1 (hu) Lurazidont tartalmazó gyógyászati készítmény
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CY2013047I1 (el) Ενωσεις διαρυλυδαντοϊνης
DK1876897T3 (da) Aktivstofkombinationer
DE602006007875D1 (de) Kapseln
DE502005005266D1 (de) Dosierpumpe
DK1737304T3 (da) Flydende koncentreret formel
DE502006002890D1 (de) Fungizide wirkstoffkombination
PL2278284T3 (pl) Zestaw ważący
EP1897558A4 (en) SOLID PREPARATION
ATE443056T1 (de) Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
DE602006020744D1 (de) Fertigspritze
ITMI20042238A1 (it) Composti per fluoropolirterei
ATE431137T1 (de) Fexofenadinlösungsformulierung
PT1901783E (pt) Ácido gentísico para estabilização de radiofármacos com 123-i
FI20050284A0 (fi) Sekoitin
EP1853274A4 (en) 2-METHYLENE-19-NOR- (20S-24S) - 1ALPHA, 25-D HYDROXYVITAMINE-D2
ITMI20052509A1 (it) Assemblati per dispositivi elettrochimici
DE602007010931D1 (de) Säurefarbstoffe
DE602006006692D1 (de) Konzentrierte flüssige triazolfungizidformulierungen
NL1031705A1 (nl) Aminozuurderivaten.